This case scrutinizes Millennium's organizational and tactical reactions to the fast progress of the biopharmaceutical market. In the early 2000s, as Millennium's competitive benefit in early-stage research study escaped and its losses installed, creator CEO Mark Levin moved the company downstream far from research study and to drug advancement and commercialization, at the same time narrowing horizontal breadth from greater than a dozen therapeutic classes to merely three.
Organization and Strategy at Millennium (B) Case Solution
In year 2005, Levin worked with Deborah Dunsire from Novartis as CEO to lead Millennium's continuing change. Apprentices are asked to position themselves in the shoes of inbound CEO Dunsire and to supply organizational proposals to carry out the brand-new approach.
PUBLICATION DATE: February 02, 2010 PRODUCT #: 710418-PDF-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Low-k Dielectrics at IBM
Time Bandits: How They Are Created Why They Are Tolerated and What Can Be Done About Them
Note on Compensation Research
International Trade Meets Intellectual Porperty: The Making of the TRIPS Agreement (Abridged)
Getting Squeezed
Note on Lead User Research
The Tale of Lynx Solution
Polaroid-Kodak, Spanish Version
The Trouble with Lenders: Subtleties in the Debt Financing of Commercial Real Estate
Deutsche Bank
